Founded in 2018 by Parkinson’s specialists Ulf Rosén and Roger Bolsöy, Intrance Medical Systems is a U.S.-based biopharmaceutical company developing and commercializing a drug-device therapy for advanced Parkinson’s disease. Its lead product, known as Lecigon® in Europe, pairs a proprietary carbidopa, entacapone and levodopa gel with a lightweight wearable pump that delivers continuous treatment directly to the small intestine. The company has FDA clearance for its IND application and controls commercial rights in the United States and several other international markets.
U.S. FDA Investigational New Drug (IND) application clearance
Compliance program
FDAIND
Quality certification
PharmAdva, LLCPharmAdva, LLC makes the MedaCube, an automated pill dispenser designed to help people take complex medication schedules correctly while keeping caregivers informed. Co-founder and neurologist Dr. Michel J. Berg invented the device for his mother, and the company’s technology grew from four University of Rochester Medical Center patents. Based in Rochester, the company says MedaCube has helped thousands of people remain independent at home and has dispensed more than 100 million pills.ROCHESTER, NY
Enable InjectionsFounded in 2010, Cincinnati-based Enable Injections develops and manufactures enFuse, a hands-free wearable drug-delivery platform that administers large-volume medications under the skin rather than intravenously. The company combines in-house design, development, and GMP-compliant manufacturing with a patient-centered approach, and its technology now supports the FDA-approved EMPAVELI Injector and other partner-branded delivery systems.CINCINNATI, OH
Laxxon MedicalFounded in 2017 by pharmaceutical professionals, Laxxon Medical develops 3D screen-printed drug delivery systems through its proprietary SPID®-Technology. Headquartered in New York City with research and development facilities in Jena, Germany, the company works with pharmaceutical partners on oral dosage forms that can control how active ingredients are released, including projects aimed at making injectable therapies available by mouth. Its platform supports development from small clinical batches through production at up to 1.5 million units per day.NEW YORK, NY
LifePulse CorporationLifePulse Corporation develops and manufactures its US-engineered Intellipulse® platform to deliver therapeutics directly into cells, with a focus on targeted oncology in human and veterinary medicine. Founded by Gary Strange, the Tampa Bay company builds on more than three decades of research, $35 million in non-dilutive funding, and over 100 issued patents. Its animal-health division has treated hundreds of dogs, cats, and horses since 2022, while its human-health program is advancing toward pancreatic-tumor trials.NEW YORK, NY